Karla Plevova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karla Plevova has a total of 736 co-authors. Here are the top co-authors by number of shared publications:
- Sarka Pospisilova
Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
25 shared publications Sarka Pospisilova
22 shared publications- Paolo Ghia
IRCSS Ospedale San Raffaele, Milan, Italy
19 shared publications Michael Doubek
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno & Faculty of Medicine, Masaryk University, Brno, Czech Republic
18 shared publicationsLarry Mansouri
14 shared publications- Kostas Stamatopoulos
Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece
13 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Springer Nature in Leukemia
- p. 1
Correction: Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study
- 16 October 2026
- Published by Springer Nature in Leukemia
- p. 1
Open AccessCorrection: Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study
- Open Access
- 11 August 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4)
Single-cell sequencing reveals transcriptional and immunogenetic diversity in stereotyped chronic lymphocytic leukemia
- 11 August 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4)
Open AccessSingle-cell sequencing reveals transcriptional and immunogenetic diversity in stereotyped chronic lymphocytic leukemia
- Open Access
Retrotransposon Activity in Chronic Lymphocytic Leukemia: Associations with RNA Splicing and TP53 Dysfunction
Retroelements (RE), particularly autonomous Long Interspersed Element-1 (LINE-1), function as potent drivers of genomic instability in various malignancies. While normally silenced by epigenetic mechanisms, their reactivation in cancer cells can drive tumor evolution. TP53 is known to repress LINE-1 transcription; however, the consequences of TP53 dysfunction on retrotransposition and transcriptional activity in chronic lymphocytic leukemia (CLL) remain unknown. To investigate the relationship between TP53 status, LINE-1 retrotranspositional potential, and transcriptomic alterations, we utilized a multi-omics approach, combining a highly sensitive NGS protocol for detecting novel LINE-1 insertions with transcriptomic profiling of transposable elements and protein-coding genes. We applied these methods to a cohort of CLL patients stratified by the presence or absence of TP53 clonal evolution and to CLL-derived cell lines MEC1 and HG3, including CRISPR/Cas9-engineered TP53 mutants. Genomic analysis revealed no evidence of widespread somatic retrotransposition, suggesting that CLL exhibits resistance against de novo LINE-1 insertions. Conversely, transcriptomic profiling uncovered distinct transposon expression signatures aligned with patterns of TP53 mutation status evolution. Notably, differentially expressed genes were significantly enriched in the RNA splicing pathway, indicating that while LINE-1 elements remain largely constrained at the genomic level, their transcriptomic activity may influence cellular rewiring, affecting patterns of TP53 mutation clonal evolution. Based on these results, we argue that the pathogenic contribution of retroelements in CLL lies in transcriptomic dysregulation and splicing alterations, rather than in direct DNA damage caused by LINE-1 insertions.
Open AccessRetrotransposon Activity in Chronic Lymphocytic Leukemia: Associations with RNA Splicing and TP53 Dysfunction
Retroelements (RE), particularly autonomous Long Interspersed Element-1 (LINE-1), function as potent drivers of genomic instability in various malignancies. While normally silenced by epigenetic mechanisms, their reactivation in cancer cells can drive tumor evolution. TP53 is known to repress LINE-1 transcription; however, the consequences of TP53 dysfunction on retrotransposition and transcriptional activity in chronic lymphocytic leukemia (CLL) remain unknown. To investigate the relationship between TP53 status, LINE-1 retrotranspositional potential, and transcriptomic alterations, we utilized a multi-omics approach, combining a highly sensitive NGS protocol for detecting novel LINE-1 insertions with transcriptomic profiling of transposable elements and protein-coding genes. We applied these methods to a cohort of CLL patients stratified by the presence or absence of TP53 clonal evolution and to CLL-derived cell lines MEC1 and HG3, including CRISPR/Cas9-engineered TP53 mutants. Genomic analysis revealed no evidence of widespread somatic retrotransposition, suggesting that CLL exhibits resistance against de novo LINE-1 insertions. Conversely, transcriptomic profiling uncovered distinct transposon expression signatures aligned with patterns of TP53 mutation status evolution. Notably, differentially expressed genes were significantly enriched in the RNA splicing pathway, indicating that while LINE-1 elements remain largely constrained at the genomic level, their transcriptomic activity may influence cellular rewiring, affecting patterns of TP53 mutation clonal evolution. Based on these results, we argue that the pathogenic contribution of retroelements in CLL lies in transcriptomic dysregulation and splicing alterations, rather than in direct DNA damage caused by LINE-1 insertions.
- Open Access
- 11 April 2026
- Published by Springer Nature in Human Genomics
- Vol. 20 (1)
Leveraging a spectrum of cytogenomics methods for profiling complex karyotypes in chronic lymphocytic leukemia
Background: A highly complex karyotype (high-CK) is a key biomarker of poor prognosis in chronic lymphocytic leukemia (CLL). While conventional methods lack the resolution to fully characterize complex structural variants (SVs), emerging technologies such as short-read WGS (sr-WGS), nanopore sequencing (ONT), optical genome mapping (OGM), and chromatin conformation capture (Micro-C) offer powerful tools for high-resolution SVs analysis, illuminating the genomic architecture underlying CLL. Methods: We selected nine CLL cases bearing diverse genomic alterations. Each underwent routine diagnostic evaluation via chromosome banding analysis (CBA), multicolor fluorescence in situ hybridization (mFISH), and chromosomal microarray (CMA) and was further analyzed using sr-WGS, ONT, OGM, and Micro-C. We performed a comprehensive comparison of copy number variants (CNVs) and SVs across all methods. Results: Across five methods (CMA, ONT, OGM, sr-WGS, Micro-C), 56.3% (179/318) of CNVs were consistently detected. A high-confidence CNV set, defined as those identified by ≥ 3 methods, comprised 70.4% (224/318). SV detection varied by genome complexity: 2910 unique breakends (BNDs) were identified, with only 10.9% (320/2910) supported by all methods. A high-confidence SV set, supported by ≥ 3 methods, included 20.4% (595/2910) of BNDs. Dicentric chromosomes (DICs) and complex derivative chromosomes (CDERs), particularly those involving BNDs near centromeric or telomeric regions, were the most difficult to resolve. Micro-C fully confirmed 71.4% (5/7) of CDERs and all ten DICs. Overall, Micro-C aligned best with classical cytogenetics, confirming 85.5% (47/55) of aberrations, followed by OGM (65.5%) and both ONT and sr-WGS (56.4%). Conclusion: Each technology offers unique insights into the leukemia genome. Combining classical cytogenetics with high-throughput methods improves the detection of structural complexity and clinically relevant alterations.
- 11 April 2026
- Published by Springer Nature in Human Genomics
- Vol. 20 (1)
Open AccessLeveraging a spectrum of cytogenomics methods for profiling complex karyotypes in chronic lymphocytic leukemia
Background: A highly complex karyotype (high-CK) is a key biomarker of poor prognosis in chronic lymphocytic leukemia (CLL). While conventional methods lack the resolution to fully characterize complex structural variants (SVs), emerging technologies such as short-read WGS (sr-WGS), nanopore sequencing (ONT), optical genome mapping (OGM), and chromatin conformation capture (Micro-C) offer powerful tools for high-resolution SVs analysis, illuminating the genomic architecture underlying CLL. Methods: We selected nine CLL cases bearing diverse genomic alterations. Each underwent routine diagnostic evaluation via chromosome banding analysis (CBA), multicolor fluorescence in situ hybridization (mFISH), and chromosomal microarray (CMA) and was further analyzed using sr-WGS, ONT, OGM, and Micro-C. We performed a comprehensive comparison of copy number variants (CNVs) and SVs across all methods. Results: Across five methods (CMA, ONT, OGM, sr-WGS, Micro-C), 56.3% (179/318) of CNVs were consistently detected. A high-confidence CNV set, defined as those identified by ≥ 3 methods, comprised 70.4% (224/318). SV detection varied by genome complexity: 2910 unique breakends (BNDs) were identified, with only 10.9% (320/2910) supported by all methods. A high-confidence SV set, supported by ≥ 3 methods, included 20.4% (595/2910) of BNDs. Dicentric chromosomes (DICs) and complex derivative chromosomes (CDERs), particularly those involving BNDs near centromeric or telomeric regions, were the most difficult to resolve. Micro-C fully confirmed 71.4% (5/7) of CDERs and all ten DICs. Overall, Micro-C aligned best with classical cytogenetics, confirming 85.5% (47/55) of aberrations, followed by OGM (65.5%) and both ONT and sr-WGS (56.4%). Conclusion: Each technology offers unique insights into the leukemia genome. Combining classical cytogenetics with high-throughput methods improves the detection of structural complexity and clinically relevant alterations.
- Open Access
- 19 September 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (12) , 2957-2967
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study
In chronic lymphocytic leukemia (CLL), the role of complex karyotype (CK) for prognostic stratification remains a topic of debate, and the impact of specific cytogenetic abnormalities is still unclear. This study aims to investigate the clinical and biological features of CLL with t(14;19)(q32;q13) (tCLL) involving the BCL3 gene. Patients with tCLL were younger and more commonly presented unmutated IGHV gene, subset #8 stereotypy, trisomy of chromosome 12, and complex karyotype than other patients without t(14;19) (oCLL). The presence of t(14;19) was associated with a shorter time to treatment and overall survival compared to oCLL. Gene expression analysis revealed a unique transcriptome profile in tCLL, characterized by the upregulation of BCL3 and the activation of B-cell receptor, PI3K-Akt. Conversely, apoptosis-related pathways were suppressed in tCLL. While the BTK gene was upregulated, the BCL2L11 gene, coding for the pro-apoptotic protein BIM, was downregulated. Notably, patients with tCLL were characterized by a trend ( p = 0.058) for a longer time to the next treatment with BTK inhibitors (BTKi) compared to those treated with a venetoclax-based (Ven-based) regimen. We underscore the adverse outcomes of tCLL, its distinct molecular features and gene expression patterns. Therefore, our data suggest that identifying tCLL could help tailor therapeutic approaches.
- 19 September 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (12) , 2957-2967
Open AccessClinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study
In chronic lymphocytic leukemia (CLL), the role of complex karyotype (CK) for prognostic stratification remains a topic of debate, and the impact of specific cytogenetic abnormalities is still unclear. This study aims to investigate the clinical and biological features of CLL with t(14;19)(q32;q13) (tCLL) involving the BCL3 gene. Patients with tCLL were younger and more commonly presented unmutated IGHV gene, subset #8 stereotypy, trisomy of chromosome 12, and complex karyotype than other patients without t(14;19) (oCLL). The presence of t(14;19) was associated with a shorter time to treatment and overall survival compared to oCLL. Gene expression analysis revealed a unique transcriptome profile in tCLL, characterized by the upregulation of BCL3 and the activation of B-cell receptor, PI3K-Akt. Conversely, apoptosis-related pathways were suppressed in tCLL. While the BTK gene was upregulated, the BCL2L11 gene, coding for the pro-apoptotic protein BIM, was downregulated. Notably, patients with tCLL were characterized by a trend ( p = 0.058) for a longer time to the next treatment with BTK inhibitors (BTKi) compared to those treated with a venetoclax-based (Ven-based) regimen. We underscore the adverse outcomes of tCLL, its distinct molecular features and gene expression patterns. Therefore, our data suggest that identifying tCLL could help tailor therapeutic approaches.
- Open Access
- 4 September 2025
- Published by Wiley in Molecular Oncology
- Vol. 19 (10) , 2764-2775
Hypomethylating agents increase L1 retroelement expression without inducing novel insertions in myeloid malignancies
Retroelements in the human genome are silenced via multiple mechanisms, including DNA methylation, to prevent their potential mutagenic effect. Retroelement activity, demonstrated by their expression and somatic retrotransposition events, was shown to be deregulated in multiple tumors but not yet in leukemia. We hypothesized that treatment with hypomethylating agents, commonly used in myelodysplastic syndromes and acute myeloid leukemia, could lead to increased retroelement activity and somatic retrotranspositions, thus contributing to disease progression. To address this hypothesis, we induced the expression of ORF1p protein with hypomethylating agents in DAMI and HL‐60 myeloid cell lines. To study whether long‐term hypomethylating agent therapy induces somatic retrotranspositions, we analyzed (i) both cell lines treated for 4 weeks, and (ii) sequential samples from 17 patients with myelodysplastic syndrome treated with hypomethylating agents. Using a sensitive next‐generation sequencing (NGS)‐based method, no retroelement events were identified. To conclude, we show that although hypomethylating agents induce the expression of LINE‐1‐encoded proteins in myeloid cell lines, de novo somatic retrotransposition events do not arise during the long‐term exposure to these agents.
- 4 September 2025
- Published by Wiley in Molecular Oncology
- Vol. 19 (10) , 2764-2775
Open AccessHypomethylating agents increase L1 retroelement expression without inducing novel insertions in myeloid malignancies
Retroelements in the human genome are silenced via multiple mechanisms, including DNA methylation, to prevent their potential mutagenic effect. Retroelement activity, demonstrated by their expression and somatic retrotransposition events, was shown to be deregulated in multiple tumors but not yet in leukemia. We hypothesized that treatment with hypomethylating agents, commonly used in myelodysplastic syndromes and acute myeloid leukemia, could lead to increased retroelement activity and somatic retrotranspositions, thus contributing to disease progression. To address this hypothesis, we induced the expression of ORF1p protein with hypomethylating agents in DAMI and HL‐60 myeloid cell lines. To study whether long‐term hypomethylating agent therapy induces somatic retrotranspositions, we analyzed (i) both cell lines treated for 4 weeks, and (ii) sequential samples from 17 patients with myelodysplastic syndrome treated with hypomethylating agents. Using a sensitive next‐generation sequencing (NGS)‐based method, no retroelement events were identified. To conclude, we show that although hypomethylating agents induce the expression of LINE‐1‐encoded proteins in myeloid cell lines, de novo somatic retrotransposition events do not arise during the long‐term exposure to these agents.
- Open Access
- 30 June 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (9) , 2076-2086
Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms
Recurrent mutations in the third base of U1 spliceosomal RNA responsible for marked splicing and expression abnormalities have been described in chronic lymphocytic leukemia (CLL) and some solid tumors. However, the clinical significance of these mutations in large and independent CLL cohorts as well as their presence in other B-cell neoplasms is unknown. Here we characterized U1 mutations in 1670 CLL and 363 mature B-cell lymphomas. We confirmed that the g.3A>C U1 mutation is found in 3.5% of CLL, which conferred rapid disease progression independently of the main biological and clinical prognostic markers of the disease. Additionally, a recurrent g.9C>T mutation was found in 1.5% of CLL causing downstream splicing alterations and associated with adverse prognosis. We also identified a g.4C>T mutation in 10% of diffuse large B-cell lymphomas of the germinal center subtype and a g.7A>G mutation in 30% of EBV-negative Burkitt lymphomas, both of which altered the splicing pattern of multiple genes. This study reveals novel, recurrent, and tumor-specific U1 mutations in mature B-cell neoplasms with biological and prognostic implications, thus establishing U1 as a novel pan-B-cell malignancy driver gene.
- 30 June 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (9) , 2076-2086
Open AccessDisease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms
Recurrent mutations in the third base of U1 spliceosomal RNA responsible for marked splicing and expression abnormalities have been described in chronic lymphocytic leukemia (CLL) and some solid tumors. However, the clinical significance of these mutations in large and independent CLL cohorts as well as their presence in other B-cell neoplasms is unknown. Here we characterized U1 mutations in 1670 CLL and 363 mature B-cell lymphomas. We confirmed that the g.3A>C U1 mutation is found in 3.5% of CLL, which conferred rapid disease progression independently of the main biological and clinical prognostic markers of the disease. Additionally, a recurrent g.9C>T mutation was found in 1.5% of CLL causing downstream splicing alterations and associated with adverse prognosis. We also identified a g.4C>T mutation in 10% of diffuse large B-cell lymphomas of the germinal center subtype and a g.7A>G mutation in 30% of EBV-negative Burkitt lymphomas, both of which altered the splicing pattern of multiple genes. This study reveals novel, recurrent, and tumor-specific U1 mutations in mature B-cell neoplasms with biological and prognostic implications, thus establishing U1 as a novel pan-B-cell malignancy driver gene.
- Open Access
In vitro culture of leukemic cells in collagen scaffolds and carboxymethyl cellulose-polyethylene glycol gel
Background: Chronic lymphocytic leukemia (CLL) is a common adult leukemia characterized by the accumulation of neoplastic mature B cells in blood, bone marrow, lymph nodes, and spleen. The disease biology remains unresolved in many aspects, including the processes underlying the disease progression and relapses. However, studying CLL in vitro poses a considerable challenge due to its complexity and dependency on the microenvironment. Several approaches are utilized to overcome this issue, such as co-culture of CLL cells with other cell types, supplementing culture media with growth factors, or setting up a three-dimensional (3D) culture. Previous studies have shown that 3D cultures, compared to conventional ones, can lead to enhanced cell survival and altered gene expression. 3D cultures can also give valuable information while testing treatment response in vitro since they mimic the cell spatial organization more accurately than conventional culture. Methods: In our study, we investigated the behavior of CLL cells in two types of material: (i) solid porous collagen scaffolds and (ii) gel composed of carboxymethyl cellulose and polyethylene glycol (CMC-PEG). We studied CLL cells’ distribution, morphology, and viability in these materials by a transmitted-light and confocal microscopy. We also measured the metabolic activity of cultured cells. Additionally, the expression levels of MYC, VCAM1, MCL1, CXCR4, and CCL4 genes in CLL cells were studied by qPCR to observe whether our novel culture approaches lead to increased adhesion, lower apoptotic rates, or activation of cell signaling in relation to the enhanced contact with co-cultured cells. Results: Both materials were biocompatible, translucent, and permeable, as assessed by metabolic assays, cell staining, and microscopy. While collagen scaffolds featured easy manipulation, washability, transferability, and biodegradability, CMC-PEG was advantageous for its easy preparation process and low variability in the number of accommodated cells. Both materials promoted cell-to-cell and cell-to-matrix interactions due to the scaffold structure and generation of cell aggregates. The metabolic activity of CLL cells cultured in CMC-PEG gel was similar to or higher than in conventional culture. Compared to the conventional culture, there was (i) a lower expression of VCAM1 in both materials, (ii) a higher expression of CCL4 in collagen scaffolds, and (iii) a lower expression of CXCR4 and MCL1 (transcript variant 2) in collagen scaffolds, while it was higher in a CMC-PEG gel. Hence, culture in the material can suppress the expression of a pro-apoptotic gene (MCL1 in collagen scaffolds) or replicate certain gene expression patterns attributed to CLL cells in lymphoid organs (low CXCR4, high CCL4 in collagen scaffolds) or blood (high CXCR4 in CMC-PEG).
Open AccessIn vitro culture of leukemic cells in collagen scaffolds and carboxymethyl cellulose-polyethylene glycol gel
Background: Chronic lymphocytic leukemia (CLL) is a common adult leukemia characterized by the accumulation of neoplastic mature B cells in blood, bone marrow, lymph nodes, and spleen. The disease biology remains unresolved in many aspects, including the processes underlying the disease progression and relapses. However, studying CLL in vitro poses a considerable challenge due to its complexity and dependency on the microenvironment. Several approaches are utilized to overcome this issue, such as co-culture of CLL cells with other cell types, supplementing culture media with growth factors, or setting up a three-dimensional (3D) culture. Previous studies have shown that 3D cultures, compared to conventional ones, can lead to enhanced cell survival and altered gene expression. 3D cultures can also give valuable information while testing treatment response in vitro since they mimic the cell spatial organization more accurately than conventional culture. Methods: In our study, we investigated the behavior of CLL cells in two types of material: (i) solid porous collagen scaffolds and (ii) gel composed of carboxymethyl cellulose and polyethylene glycol (CMC-PEG). We studied CLL cells’ distribution, morphology, and viability in these materials by a transmitted-light and confocal microscopy. We also measured the metabolic activity of cultured cells. Additionally, the expression levels of MYC, VCAM1, MCL1, CXCR4, and CCL4 genes in CLL cells were studied by qPCR to observe whether our novel culture approaches lead to increased adhesion, lower apoptotic rates, or activation of cell signaling in relation to the enhanced contact with co-cultured cells. Results: Both materials were biocompatible, translucent, and permeable, as assessed by metabolic assays, cell staining, and microscopy. While collagen scaffolds featured easy manipulation, washability, transferability, and biodegradability, CMC-PEG was advantageous for its easy preparation process and low variability in the number of accommodated cells. Both materials promoted cell-to-cell and cell-to-matrix interactions due to the scaffold structure and generation of cell aggregates. The metabolic activity of CLL cells cultured in CMC-PEG gel was similar to or higher than in conventional culture. Compared to the conventional culture, there was (i) a lower expression of VCAM1 in both materials, (ii) a higher expression of CCL4 in collagen scaffolds, and (iii) a lower expression of CXCR4 and MCL1 (transcript variant 2) in collagen scaffolds, while it was higher in a CMC-PEG gel. Hence, culture in the material can suppress the expression of a pro-apoptotic gene (MCL1 in collagen scaffolds) or replicate certain gene expression patterns attributed to CLL cells in lymphoid organs (low CXCR4, high CCL4 in collagen scaffolds) or blood (high CXCR4 in CMC-PEG).
- Open Access
- 21 May 2024
- Published by Wiley in Molecular Oncology
- Vol. 18 (10) , 2541-2553
Unveiling the dynamics and molecular landscape of a rare chronic lymphocytic leukemia subpopulation driving refractoriness: insights from single‐cell RNA sequencing
Early identification of resistant cancer cells is currently a major challenge, as their expansion leads to refractoriness. To capture the dynamics of these cells, we made a comprehensive analysis of disease progression and treatment response in a chronic lymphocytic leukemia (CLL) patient using a combination of single‐cell and bulk genomic methods. At diagnosis, the patient presented with unfavorable genetic markers, including notch receptor 1 (NOTCH1) mutation and loss(11q). The initial and subsequent treatment lines did not lead to a durable response and the patient developed refractory disease. Refractory CLL cells featured substantial dysregulation in B‐cell phenotypic markers such as human leukocyte antigen (HLA) genes, immunoglobulin (IG) genes, CD19 molecule (CD19), membrane spanning 4‐domains A1 (MS4A1; previously known as CD20), CD79a molecule (CD79A) and paired box 5 (PAX5), indicating B‐cell de‐differentiation and disease transformation. We described the clonal evolution and characterized in detail two cell populations that emerged during the refractory disease phase, differing in the presence of high genomic complexity. In addition, we successfully tracked the cells with high genomic complexity back to the time before treatment, where they formed a rare subpopulation. We have confirmed that single‐cell RNA sequencing enables the characterization of refractory cells and the monitoring of their development over time.
- 21 May 2024
- Published by Wiley in Molecular Oncology
- Vol. 18 (10) , 2541-2553
Open AccessUnveiling the dynamics and molecular landscape of a rare chronic lymphocytic leukemia subpopulation driving refractoriness: insights from single‐cell RNA sequencing
Early identification of resistant cancer cells is currently a major challenge, as their expansion leads to refractoriness. To capture the dynamics of these cells, we made a comprehensive analysis of disease progression and treatment response in a chronic lymphocytic leukemia (CLL) patient using a combination of single‐cell and bulk genomic methods. At diagnosis, the patient presented with unfavorable genetic markers, including notch receptor 1 (NOTCH1) mutation and loss(11q). The initial and subsequent treatment lines did not lead to a durable response and the patient developed refractory disease. Refractory CLL cells featured substantial dysregulation in B‐cell phenotypic markers such as human leukocyte antigen (HLA) genes, immunoglobulin (IG) genes, CD19 molecule (CD19), membrane spanning 4‐domains A1 (MS4A1; previously known as CD20), CD79a molecule (CD79A) and paired box 5 (PAX5), indicating B‐cell de‐differentiation and disease transformation. We described the clonal evolution and characterized in detail two cell populations that emerged during the refractory disease phase, differing in the presence of high genomic complexity. In addition, we successfully tracked the cells with high genomic complexity back to the time before treatment, where they formed a rare subpopulation. We have confirmed that single‐cell RNA sequencing enables the characterization of refractory cells and the monitoring of their development over time.
- 3 May 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (5) , 733-736
The 1+Million Genomes Minimal Dataset for Cancer
- 3 May 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (5) , 733-736
The 1+Million Genomes Minimal Dataset for Cancer